OLD National Bancorp IN Has $479 Million Holdings in Eli Lilly and Company $LLY

OLD National Bancorp IN reduced its stake in Eli Lilly and Company (NYSE:LLY) by 0.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 627,781 shares of the company’s stock after selling 1,159 shares during the period. Eli Lilly and Company comprises approximately 8.2% of OLD National Bancorp IN’s investment portfolio, making the stock its 2nd largest position. OLD National Bancorp IN owned 0.07% of Eli Lilly and Company worth $478,997,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in LLY. Matrix Trust Co boosted its position in Eli Lilly and Company by 50.7% in the third quarter. Matrix Trust Co now owns 660 shares of the company’s stock valued at $504,000 after buying an additional 222 shares in the last quarter. Alpha Wealth Funds LLC acquired a new position in shares of Eli Lilly and Company during the third quarter worth $884,000. Intergy Private Wealth LLC lifted its stake in shares of Eli Lilly and Company by 6.1% in the 3rd quarter. Intergy Private Wealth LLC now owns 314 shares of the company’s stock valued at $240,000 after acquiring an additional 18 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 23,807 shares of the company’s stock valued at $18,165,000 after acquiring an additional 312 shares in the last quarter. Finally, Parcion Private Wealth LLC grew its position in Eli Lilly and Company by 51.6% during the 3rd quarter. Parcion Private Wealth LLC now owns 1,928 shares of the company’s stock worth $1,471,000 after acquiring an additional 656 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive clinical data and pipeline momentum: MarketBeat and other coverage highlight strong orforglipron (oral) maintenance data and very high-weight-loss results for retatrutide, supporting Lilly’s 2026 outlook and the potential for new, recurring revenue streams if approvals succeed. (Pipeline upside is a major growth driver.)
• Positive Sentiment: Analysts raising estimates: Zacks and other outlets have lifted near‑term EPS estimates for Lilly, indicating improving sell‑side expectations for upcoming quarters — a supportive signal for valuation and sentiment.
• Positive Sentiment: Breast‑cancer trial update adds diversification to growth story: Lilly announced updated meaningful data on a breast cancer treatment, which could broaden the company’s revenue base beyond GLP‑1s and reduce single‑product risk. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment
• Neutral Sentiment: Stock‑split speculation: Commentary that LLY is a top stock‑split candidate in 2026 may boost retail interest and liquidity if management acts, but it is not a fundamental earnings catalyst on its own. Eli Lilly (LLY) a Top Stock Split Candidate in 2026
• Neutral Sentiment: Technical/band commentary: Some technical analysts are flagging buy zones and short‑term ranges for LLY, which can influence short‑term trading flows but not fundamentals. Eli Lilly & Company (LLY): Buyers looking for rally between $1144.4 – $1196.17
• Neutral Sentiment: M&A interest in niche assets: Analysis suggesting Lilly might target small biotech assets (e.g., Abivax) is speculative — could be accretive but not immediate. Abivax: Here’s Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
• Negative Sentiment: Competitive pressure from Novo Nordisk’s newly FDA‑approved oral Wegovy pill: Novo’s approval and planned U.S. launch (early January) has pushed investors to re‑rate competitive dynamics in the obesity/GLP‑1 market — a near‑term headwind for Lilly’s market share and pricing expectations. Focus: Lilly, Novo lock horns in India’s obesity drug race
• Negative Sentiment: India and generics risk: Reports that Lilly and Novo are racing to capture India’s obesity market ahead of cheaper generics due in March raise margin and volume risks in a large market — increased competition can pressure growth forecasts. Eli Lilly and Novo Nordisk Battle for India’s Fast‑Growing Obesity‑Drug Market
• Negative Sentiment: Analyst downgrade / cautionary market commentary: A recent Seeking Alpha piece downgraded the stock, reflecting concerns about valuation, tolerability issues for next‑gen drugs (discontinuation rates), and near‑term competitive threats — a sentiment headwind for momentum investors. Eli Lilly: Mr. Market Finally Woke Up, But I’m Not Out Yet (Rating Downgrade)

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. CICC Research raised their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Daiwa Capital Markets set a $1,230.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Bank of America reduced their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. Finally, BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Thursday, December 4th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,077.06 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a 50 day simple moving average of $976.10 and a two-hundred day simple moving average of $837.36. The company has a market capitalization of $1.02 trillion, a PE ratio of 52.69, a P/E/G ratio of 1.08 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm posted $1.18 EPS. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.